CN103054819B - 一种注射用更昔洛韦及其制备方法 - Google Patents
一种注射用更昔洛韦及其制备方法 Download PDFInfo
- Publication number
- CN103054819B CN103054819B CN201310038827.7A CN201310038827A CN103054819B CN 103054819 B CN103054819 B CN 103054819B CN 201310038827 A CN201310038827 A CN 201310038827A CN 103054819 B CN103054819 B CN 103054819B
- Authority
- CN
- China
- Prior art keywords
- ganciclovir
- injection
- preparation
- freezing
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 229960002963 ganciclovir Drugs 0.000 title claims abstract description 62
- 238000002347 injection Methods 0.000 title claims abstract description 32
- 239000007924 injection Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title abstract description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 22
- 238000001035 drying Methods 0.000 claims abstract description 14
- 230000008014 freezing Effects 0.000 claims abstract description 12
- 238000007710 freezing Methods 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims abstract description 12
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 54
- 238000004108 freeze drying Methods 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 17
- 239000003002 pH adjusting agent Substances 0.000 claims description 8
- 238000000859 sublimation Methods 0.000 claims description 8
- 230000008022 sublimation Effects 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000008176 lyophilized powder Substances 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 abstract description 19
- 239000000126 substance Substances 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000008859 change Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 22
- 238000000034 method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- 238000005352 clarification Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 241000700584 Simplexvirus Species 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 239000004411 aluminium Substances 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011265 semifinished product Substances 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000009351 contact transmission Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- -1 ganciclovir compound Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 萎缩 | 分层 | 结块 | 废品率 |
实施例1 | 2 | 0 | 3 | 0.5% |
实施例2 | 3 | 0 | 4 | 0.7% |
实施例3 | 3 | 1 | 2 | 0.6% |
对比实施例1 | 50 | 20 | 18 | 8.8% |
对比实施例2 | 53 | 21 | 15 | 8.9% |
对比实施例3 | 15 | 12 | 20 | 4.7% |
组别 | 复溶速度 | 澄清度 | 可见异物 |
实施例1 | 很快,25秒内完全溶解 | 溶液均无色、澄清 | 均合格 |
实施例2 | 很快,25秒内完全溶解 | 溶液均无色、澄清 | 均合格 |
实施例3 | 很快,25秒内完全溶解 | 溶液均无色、澄清 | 均合格 |
对比实施例1 | 快,35-40秒内完全溶解 | 溶液均无色、澄清 | 均合格 |
对比实施例2 | 快,30-35秒完全溶解 | 溶液均无色、澄清 | 均合格 |
对比实施例3 | 快,25秒内完全溶解 | 溶液均无色、澄清 | 均合格 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310038827.7A CN103054819B (zh) | 2013-01-31 | 2013-01-31 | 一种注射用更昔洛韦及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310038827.7A CN103054819B (zh) | 2013-01-31 | 2013-01-31 | 一种注射用更昔洛韦及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103054819A CN103054819A (zh) | 2013-04-24 |
CN103054819B true CN103054819B (zh) | 2014-07-16 |
Family
ID=48097919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310038827.7A Active CN103054819B (zh) | 2013-01-31 | 2013-01-31 | 一种注射用更昔洛韦及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103054819B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104414967A (zh) * | 2013-09-06 | 2015-03-18 | 康普药业股份有限公司 | 一种更昔洛韦注射液及其制备方法 |
CN104666303B (zh) * | 2015-01-30 | 2017-01-25 | 湖南科伦制药有限公司 | 一种注射用更昔洛韦的冷冻干燥工艺 |
CN106924194A (zh) * | 2015-12-31 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 一种长效的药用组合物及制备方法 |
CN107213123A (zh) * | 2017-07-23 | 2017-09-29 | 南京正宽医药科技有限公司 | 一种注射用盐酸氨溴索及其制备方法 |
CN107550872A (zh) * | 2017-09-30 | 2018-01-09 | 平光制药股份有限公司 | 一种注射用更昔洛韦冻干粉针剂的制备方法 |
CN110051635B (zh) * | 2019-03-13 | 2021-10-01 | 安庆瑄宇医药科技有限公司 | 一种更昔洛韦粉针剂的制备方法及其所用的压滤机 |
CN110585141A (zh) * | 2019-09-19 | 2019-12-20 | 湖北科益药业股份有限公司 | 一种稳定的更昔洛韦冻干粉针剂 |
CN110559266A (zh) * | 2019-09-19 | 2019-12-13 | 湖北科益药业股份有限公司 | 一种注射用更昔洛韦的冷冻干燥工艺 |
CN110613688A (zh) * | 2019-09-26 | 2019-12-27 | 无锡凯夫制药有限公司 | 一种制备更昔洛韦的冻干方法 |
CN111973564A (zh) * | 2020-09-02 | 2020-11-24 | 海南倍特药业有限公司 | 一种注射用更昔洛韦组合物及其冷冻干燥工艺 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780051A (zh) * | 2008-05-08 | 2010-07-21 | 海南斯达制药有限公司 | 炎琥宁及其冻干粉针剂的制备方法 |
CN102210686A (zh) * | 2011-04-07 | 2011-10-12 | 罗诚 | 一种含更昔洛韦化合物的药物组合物及其制备方法 |
CN102274197A (zh) * | 2011-07-19 | 2011-12-14 | 江苏奥赛康药业股份有限公司 | 一种注射用更昔洛韦组合物及其制备方法 |
-
2013
- 2013-01-31 CN CN201310038827.7A patent/CN103054819B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780051A (zh) * | 2008-05-08 | 2010-07-21 | 海南斯达制药有限公司 | 炎琥宁及其冻干粉针剂的制备方法 |
CN102210686A (zh) * | 2011-04-07 | 2011-10-12 | 罗诚 | 一种含更昔洛韦化合物的药物组合物及其制备方法 |
CN102274197A (zh) * | 2011-07-19 | 2011-12-14 | 江苏奥赛康药业股份有限公司 | 一种注射用更昔洛韦组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103054819A (zh) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103054819B (zh) | 一种注射用更昔洛韦及其制备方法 | |
CN102144981A (zh) | 一种盐酸吉西他滨冻干粉针剂及其制备方法 | |
CN105287407A (zh) | 一种注射用磷酸特地唑胺 | |
CN101711746B (zh) | 一种注射用更昔洛韦冻干制剂及其制备方法 | |
CN102178681B (zh) | 一种供注射用的亚叶酸钙组合物及其制备方法 | |
CN102274197B (zh) | 一种注射用更昔洛韦组合物及其制备方法 | |
CN104434822A (zh) | 一种注射用苯磺顺阿曲库铵组合物及其制备方法与应用 | |
CN102038939B (zh) | 一种三磷酸腺苷辅酶胰岛素冻干粉针剂的制备方法 | |
CN102302461A (zh) | 一种注射用丹曲林钠冻干粉针剂及其制备方法 | |
CN104434819A (zh) | 注射用乙酰谷酰胺粉针剂药物组合物和制法 | |
CN102258488A (zh) | 一种注射用克林霉素磷酸酯组合物及其制备方法 | |
CN102276533B (zh) | 一种新的奥扎格雷钠化合物及其药物组合物 | |
CN112791103B (zh) | 一种鹿血制品及其制备方法 | |
CN103110616B (zh) | 一种注射用门冬氨酸钾镁冻干粉针制剂及其制备方法 | |
CN103371978B (zh) | 采用含乙醇溶剂制备的冻干粉针剂 | |
CN102397259A (zh) | 注射用辅酶a及其生产工艺 | |
CN100544723C (zh) | 含有亚叶酸钠的冻干粉针及其制备方法 | |
CN103371979A (zh) | 一种甲泼尼龙琥珀酸钠冻干粉针剂 | |
CN104490799A (zh) | 一种注射用间苯三酚冻干组合物及其制备方法 | |
CN102397536A (zh) | 注射用三磷酸腺苷辅酶胰岛素及其生产工艺 | |
CN101143144A (zh) | 乳酸米力农冻干粉针注射剂及其制备方法 | |
CN104324010B (zh) | 一种注射用肌苷冻干粉及其制备方法 | |
CN106674225A (zh) | 一种核黄素磷酸钠化合物及其药物组合物 | |
CN108836945A (zh) | 一种注射用穿琥宁冻干粉针剂的制备方法 | |
CN107412241A (zh) | 一种紫丁香苷药物组合物及其在治疗宫颈炎中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Ma Yuanliang Inventor after: Li Shuju Inventor after: Li Shujun Inventor before: Request for anonymity |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161011 Address after: 100190, 8 floor, No. 18 Zhongguancun Avenue, Beijing, Haidian District, 05-148 Patentee after: BEIJING WANPENG LANGGE MEDICINE TECHNOLOGY CO.,LTD. Address before: 211200, No. 1, Shandong Road, Lishui Economic Development Zone, Nanjing, Jiangsu Patentee before: NANJING ZHENGKUAN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20231124 Address after: Room 301, 3rd Floor, Building 1, No. 49 Huatuo Road, Daxing Biomedical Industry Base, Zhongguancun Science and Technology Park, Daxing District, Beijing, 102629 Patentee after: BEIJING MEDFRON MEDICINA TECHNOLOGY CO.,LTD. Address before: Room 05-148, 8th Floor, No. 18 Zhongguancun Street, Haidian District, Beijing, 100190 Patentee before: BEIJING WANPENG LANGGE MEDICINE TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right |